Catalyst Pharmaceuticals, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Coral Gables FL United States (2002)

Organization Overview

First Clinical Trial
2007
NCT00527683
First Marketed Drug
2018
amifampridine phosphate (firdapse)
First NDA Approval
2018
amifampridine phosphate (firdapse)
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Catalyst Pharmaceuticals, Inc. | CATALYST PHARMS

Active Ingredients

Marketed Drugs (1)

amifampridine phosphate (firdapse) (2018 NDA)

Drugs in Phase 3 Trials (2)

amifampridine phosphate (firdapse) (8 trials)

vigabatrin (sabril) (4 trials)

Drugs in Phase 1 Trials (1)

cpp-115 (1 trial)

Indications

Approved Indications


 

Lambert-Eaton Myasthenic Syndrome

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Behavior, Addictive (Phase 3)

Cocaine-Related Disorders (Phase 3)

Lambert-Eaton Myasthenic Syndrome (Phase 3)

Muscle Weakness (Phase 3)

Muscular Atrophy (Phase 2)

Muscular Atrophy, Spinal (Phase 2)

Myasthenia Gravis (Phase 3)

Myasthenic Syndromes, Congenital (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 3